Vandetanib Had Antitumor Activity In RET-rearranged NSC Lung Cancer Interview with:
Dr Kiyotaka Yoh

Department of Thoracic Oncology
National Cancer Center Hospital East
Kashiwa, Japan What is the background for this study? What are the main findings?

Response: LURET is multicenter, single-arm, phase II study to evaluate the efficacy and safety of vandetanib as RET inhibitor in patients with advanced RET-rearranged non-small-cell lung cancer (NSCLC). In 2012, RET rearrangements were identified as rare oncogenic alterations for NSCLC.

Among 17 eligible patients included in primary analysis, the objective response rate was 53% (95% CI 28–77), which met the primary endpoint. At the data cutoff, median progression-free survival was 4.7 months (95% CI 2.8–8.5). Overall, vandetanib was tolerated, with an adverse event profile similar to those seen in previous large population studies of vandetanib in patients with unselected NSCLC. What should readers take away from your report?

Response: Our study showed that vandetanib exhibited clinical antitumor activity in patients with advanced RET-rearranged NSCLC. Our results define RET rearrangement as a new molecular subgroup of NSCLC suitable for targeted therapy. What recommendations do you have for future research as a result of this study?

Response: Interestingly, our results showed differences in vandetanib efficacy according to the type of RET fusion. Patients with CCDC6-RET had a much higher response and a longer survival after vandetanib treatment than did those with KIF5B-RET. Further investigation is needed to elucidate whether sensitivity to RET inhibitor differed among different RET fusions forms. Is there anything else you would like to add?

Response: The RET inhibitor vandetanib is effective in RET-rearranged NSCLC patients. Although further large confirmatory studies are warranted, our results have important implications for RET-directed therapy in patients with NSCLC.

Study drug was supported by AstraZeneca and Sanofi and its subsidiary Genzyme. Thank you for your contribution to the community.


Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Yoh, Kiyotaka et al.
The Lancet Respiratory Medicine , Volume 5 , Issue 1 , 42 – 50
November 2016

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on

[wysija_form id=”5″]

No Comments

Sorry, the comment form is closed at this time.